To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

1. Patients with IIIc/IV NSCLC confirmed by histology and imaging
2. Previous treatment with anti-PD1 or anti-PDL1, and resistantance to ICIs
3. Without standard treatment regimen
4. At least one measurable target (primary tumour or metastasis) according to RECIST v1.1
5. Age ≥ 18 and ≤ 75
6. ECOG PS ≤ 2
7. Life expectancy ≥ 3 months

Exclusion Criteria:

1. Autoimmune disease that might be aggravated during treatment with an immuno-stimulating agent (patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible)
2. Immunosuppressive long-term treatment (patients necessitating a corticotherapy are eligible if they are administered in doses \< or = to the equivalent of 10 mg of prednisone daily, administration of steroids by a route resulting in minimal systemic exposure (local, intra-anal, intraocular or inhalation) are eligible).
3. Transplant patients (including stem cell transplants), HIV positive or other immune deficiency syndromes
4. Active infection by HBV or HCV Known severe hypersensitivity to monoclonal antibodies or history of anaphylactic shock, or uncontrolled asthma
5. Patient with interstitial pneumonitis or pulmonary fibrosis or any other known severe respiratory insufficiency
6. Patient already included in another clinical trial during treatment with an experimental